BMC Nephrology (Dec 2018)

Remote ischemic preconditioning to reduce contrast-induced acute kidney injury in chronic kidney disease: a randomized controlled trial

  • Ali Ghaemian,
  • Jamshid Yazdani,
  • Soheil Azizi,
  • Ali A. Farsavian,
  • Maryam Nabati,
  • Alireza Malekrah,
  • Mozhdeh Dabirian,
  • Fatemeh Espahbodi,
  • Bahareh Mirjani,
  • Hossein Mohsenipouya,
  • Javad Heshmatian

DOI
https://doi.org/10.1186/s12882-018-1169-x
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background The impact of contrast-induced acute kidney injury (CI-AKI) on patients with chronic renal disease is well-known. Remote ischemic preconditioning (RIPC) is a non-invasive method that can reduce the risk of CI-AKI, but studies on RIPC have had different results. The aim of the present study was to assess the potential impact of RIPC on CI-AKI. Methods In a randomized, double blinded, controlled trial, 132 patients with chronic renal dysfunction (glomerular filtration rate < 60 mL/min/m2) who underwent coronary angiography or angioplasty received adequate hydration. RIPC was performed in 66 patients by applying an upper arm blood pressure cuff. The cuff was inflated four times for 5 min to 50 mmHg above the systolic blood pressure, followed by deflation for 5 min. In the control group, the blood pressure cuff was inflated only to 10 mmHg below the patient’s diastolic blood pressure. The primary endpoint was an increase in serum cystatin C ≥ 10% from baseline to 48–72 h after exposure to the contrast. Results The primary endpoint was achieved in 48 (36.4%) patients (24 in each group). RIPC did not show any significant effect on the occurrence of the primary endpoint (P = 1). In addition, when the results were analyzed based on the Mehran risk score for subgroups of patients, RIPC did not reduce the occurrence of the primary endpoint (P = 0.97). Conclusions In patients at moderate-to-high risk of developing CI-AKI when an adequate hydration protocol is performed, RIPC does not have an additive effect to prevent the occurrence of CI-AKI. Trial registration The clinical trial was registered on (Identification number IRCT2016050222935N2, on December 19, 2016 as a retrospective IRCT).

Keywords